Living with inflammatory bowel disease (IBD) can be a constant battle against internal inflammation. For many patients, managing weight is also a major part of the journey. A recent review looked at how GLP-1 receptor agonists—a class of medications often used for weight loss and blood sugar control—affect people who have both IBD and obesity.
The findings show that these medications can help patients lose about 16 pounds over an 18 month period, which is similar to what the general population sees. The drugs also helped lower certain markers of inflammation in the blood, like CRP. While some improvements were noted in overall disease activity, other markers like fecal calprotectin did not show consistent changes.
There are still pieces of the puzzle missing. For example, data on how these drugs affect internal tissue (endoscopic activity) is limited. Also, while the medications can be effective for weight and inflammation, some patients reported gastrointestinal side effects that sometimes made it hard to stay on the treatment. More long-term studies are needed to see exactly how these drugs impact IBD over many years.
